Recombinant Factor VIII (Kabi Pharmaceuticals)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant Factor VIII (Kabi Pharmaceuticals)
Drug Alias NameFactor VIII (recombinant)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation
TargetsCoagulation factor X
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsHemophilia A

Other Information

ATC CodeN/A
Related LinksN/A